The results of this study led to the accelerated approval of T-DXd by the FDA in December 2019 for advanced, unresectable or metastatic HER2-positive BC pretreated after at least 2 prior HER2-targeted therapies in the metastatic setting. This evidence concerns the gene ERBB2 and breast cancer.